Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
1. A method of inhibiting tumor growth in a subject, comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds at least one human frizzled receptor (FZD) selected from the group consisting of FZD1, FZD2, FZD5, FZD7 and FZD8, wherein the antibody is selected from the group consisting of:
a) an antibody comprising:
(i) a heavy chain CDR1 comprising GFTFSHYTLS (SEQ ID NO:1), a heavy chain CDR2 comprising VISGDGSYTYYADSVKG (SEQ ID NO:2), and a heavy chain CDR3 comprising NFIKYVFAN (SEQ ID NO:3), and
(ii) a light chain CDR1 comprising SGDKLGKKYAS (SEQ ID NO:4) or SGDNIGSFYVH (SEQ ID NO:7), a light chain CDR2 comprising EKDNRPSG (SEQ ID NO:5) or DKSNRPSG (SEQ ID NO:8), and a light chain CDR3 comprising SSFAGNSLE (SEQ ID NO:6) or QSYANTLSL (SEQ ID NO:9);
(b) an antibody comprising:
(i) a heavy chain variable region having the amino acid sequence of SEQ ID NO:10; and
(ii) a light chain variable region having the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:14;
(c) an antibody encoded by the sequence of a plasmid deposited with the ATCC as accession number PTA-9540 or PTA-9541; and
(d) an antibody that competes for specific binding to the at least one human frizzled receptor with a second antibody, wherein the second antibody comprises a heavy chain variable region comprising SEQ ID NO:10 and a light chain variable region comprising SEQ ID NO:14.
2. A method of reducing the tumorigenicity of a tumor that comprises cancer stem cells in a subject, said method comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds at least one human frizzled receptor (FZD) selected from the group consisting of FZD1, FZD2, FZD5, FZD7 and FZD8, wherein the frequency of cancer stem cells in the tumor is reduced by administration of the antibody, and wherein the antibody is selected from the group consisting of:
a) an antibody comprising:
(i) a heavy chain CDR1 comprising GFTFSHYTLS (SEQ ID NO:1), a heavy chain CDR2 comprising VISGDGSYTYYADSVKG (SEQ ID NO:2), and a heavy chain CDR3 comprising NFIKYVFAN (SEQ ID NO:3), and
(ii) a light chain CDR1 comprising SGDKLGKKYAS (SEQ ID NO:4) or SGDNIGSFYVH (SEQ ID NO:7), a light chain CDR2 comprising EKDNRPSG (SEQ ID NO:5) or DKSNRPSG (SEQ ID NO:8), and a light chain CDR3 comprising SSFAGNSLE (SEQ ID NO:6) or QSYANTLSL (SEQ ID NO:9);
(b) an antibody comprising:
(i) a heavy chain variable region having the amino acid sequence of SEQ ID NO:10; and
(ii) a light chain variable region having the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:14;
(c) an antibody encoded by the sequence of a plasmid deposited with the ATCC as accession number PTA-9540 or PTA-9541; and
(d) an antibody that competes for specific binding to the at least one human frizzled receptor with a second antibody, wherein the second antibody comprises a heavy chain variable region comprising SEQ ID NO:10 and a light chain variable region comprising SEQ ID NO:14.
3. The method of claim 1 , wherein the tumor is a colorectal tumor, a breast tumor, a lung tumor, or a pancreatic tumor.
4. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds at least one human frizzled receptor (FZD) selected from the group consisting of FZD1, FZD2, FZD5, FZD7 and FZD8, wherein the antibody is selected from the group consisting of:
a) an antibody comprising:
(i) a heavy chain CDR1 comprising GFTFSHYTLS (SEQ ID NO:1), a heavy chain CDR2 comprising VISGDGSYTYYADSVKG (SEQ ID NO:2), and a heavy chain CDR3 comprising NFIKYVFAN (SEQ ID NO:3), and
(ii) a light chain CDR1 comprising SGDKLGKKYAS (SEQ ID NO:4) or SGDNIGSFYVH (SEQ ID NO:7), a light chain CDR2 comprising EKDNRPSG (SEQ ID NO:5) or DKSNRPSG (SEQ ID NO:8), and a light chain CDR3 comprising SSFAGNSLE (SEQ ID NO:6) or QSYANTLSL (SEQ ID NO:9);
(b) an antibody comprising:
(i) a heavy chain variable region having the amino acid sequence of SEQ ID NO:10; and
(ii) a light chain variable region having the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:14;
(c) an antibody encoded by the sequence of a plasmid deposited with the ATCC as accession number PTA-9540 or PTA-9541; and
(d) an antibody that competes for specific binding to the at least one human frizzled receptor with a second antibody, wherein the second antibody comprises a heavy chain variable region comprising SEQ ID NO:10 and a light chain variable region comprising SEQ ID NO:14.
5. The method of claim 4 , wherein the cancer is colorectal cancer, breast cancer, a lung cancer, or pancreatic cancer.
6. The method of claim 4 , which further comprises administering a second anti-cancer agent to the subject, wherein the second anti-cancer agent is selected from the group consisting of a chemotherapeutic agent, an angiogenesis inhibitor, and an inhibitor of Notch signaling.
7. The method of claim 4 , wherein the antibody specifically binds FZD1, FZD2, FZD5, FZD7 and FZD8.
8. The method of claim 4 , wherein the antibody comprises:
(i) a heavy chain CDR1 comprising GFTFSHYTLS (SEQ ID NO:1), a heavy chain CDR2 comprising VISGDGSYTYYADSVKG (SEQ ID NO:2), and a heavy chain CDR3 comprising NFIKYVFAN (SEQ ID NO:3), and
(ii) a light chain CDR1 comprising SGDNIGSFYVH (SEQ ID NO:7), a light chain CDR2 comprising DKSNRPSG (SEQ ID NO:8), and a light chain CDR3 comprising QSYANTLSL (SEQ ID NO:9).
9. The method of claim 4 , wherein the antibody is encoded by the sequence of a plasmid deposited with the ATCC as accession number PTA-9541.
10. The method of claim 4 , wherein the antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO:10, and a light chain variable region having the amino acid sequence of SEQ ID NO:14.
11. The method of claim 4 , wherein the antibody is a monoclonal antibody.
12. The method of claim 4 , wherein the antibody is a human antibody.
13. The method of claim 4 , wherein the antibody is a humanized antibody.
14. The method of claim 4 , wherein the antibody is an IgG2 antibody.
15. The method of claim 4 , wherein the antibody binds to the at least one human frizzled receptor with a K D of about 100 nM or less.
16. The method of claim 4 , wherein the antibody is an antagonist of the at least one human frizzled receptor.
17. The method of claim 1 , which further comprises administering a second anti-cancer agent to the subject, wherein the second anti-cancer agent is selected from the group consisting of a chemotherapeutic agent, an angiogenesis inhibitor, and an inhibitor of Notch signaling.
18. The method of claim 1 , wherein the antibody comprises:
(i) a heavy chain CDR1 comprising GFTFSHYTLS (SEQ ID NO:1), a heavy chain CDR2 comprising VISGDGSYTYYADSVKG (SEQ ID NO:2), and a heavy chain CDR comprising NFIKYVFAN (SEQ ID NO:3), and
(ii) a light chain CDR1 comprising SGDNIGSFYVH (SEQ ID NO:7), a light chain CDR2 comprising DKSNRPSG (SEQ ID NO:8), and a light chain CDR3 comprising QSYANTLSL (SEQ ID NO:9).
19. The method of claim 1 , wherein the antibody is encoded by the sequence of a plasmid deposited with the ATCC as accession number PTA-9541.
20. The method of claim 1 , wherein the antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO:10 and a light chain variable region having the amino acid sequence of SEQ ID NO:14.
21. The method of claim 4 , wherein the antibody is an antigen-binding antibody fragment.